CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER (cefotetan disodium) by B. Braun is clinical pharmacology: high plasma levels of cefotetan are attained after intravenous and intramuscular administration of single doses to normal volunteers. Approved for incidence of certain postoperative infections in patients undergoing surgical procedures, potentially contaminated (e. First approved in 2007.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
Cefotetan disodium is a second-generation cephalosporin antibiotic administered as an intravenous or intramuscular injection in a duplex container with dextrose. It works by inhibiting bacterial cell wall synthesis and is indicated for prophylaxis of postoperative infections in patients undergoing surgical procedures.
Product is approaching loss of exclusivity, signaling a contraction phase for the brand team with reduced headcount and focus shifting to generic management.
CLINICAL PHARMACOLOGY: High plasma levels of cefotetan are attained after intravenous and intramuscular administration of single doses to normal volunteers. PLASMA CONCENTRATIONS AFTER 1 GRAM INTRAVENOUS OR INTRAMUSCULAR DOSE Mean Plasma Concentration (mcg/mL) Time After Injection Route 15 min 30…
Worked on CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER at B. Braun? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on Cefotetan as it approaches LOE offers limited growth opportunities but valuable experience in managing mature, high-volume injectable products in competitive surgical markets. Roles will focus on cost optimization, formulary positioning, and transition planning rather than innovation or expansion.